Skip to main content

Table 2 Urinary evaluation of the participants

From: The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study

Group A Pre-observation Post-observation P value
Frequency 11.0 (1.0) 11.0 (1.0) 0.200
Urgency episodes 6.5 (1.0) 7.0 (1.0) 0.093
Nocturia episodes 2.0 (1.0) 1.0 (1.0) 0.231
Incontinence episodes 2.0 (1.0) 2.0 (2.0) 0.332
Incontinence pads 5.0 (2.0) 5.0 (2.0) 0.231
Voided volume (ml) 121.5 (31.0) 114.5 (27.0) 0.001
Group B Pre-treatment Post-treatment P value
Frequency 11.0 (2.0) 9.0 (2.0) < 0.001
Urgency episodes 7.0 (2.0) 4.0 (2.0) < 0.001
Nocturia 2.0 (1.0) 1.0 (1.0) < 0.001
Incontinence episodes 2.0 (1.0) 1.0 (1.0) < 0.001
Incontinence pads 4.0 (2.0) 2.0 (2.0) < 0.001
Voided volume (ml) 117.0 (33.0) 148.0 (26.0) < 0.001
\